Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess antiviral activity when administered alone for 3 days
or in combination with peginterferon and ribavirin for 12 weeks. This study will also
evaluate the safety and tolerability of treatment with VCH-222 when given alone or in
combination with peginterferon and ribavirin.
The study will also evaluate the pharmacokinetic profile of VCH-222 in HCV infected subjects.